News – Page 818 – Endpoints News

Roche-backed Dicerna pushes into the pack racing toward the blockbuster hep B goal line, armed with PhI data

5 years ago

Versant funds TCR therapy biotech T-knife's $78M+ Series A to boost humanized T cell mice platform

5 years ago

FDA approves GSK's BCMA drug, marking a rocky return to cancer for the British giant

5 years ago

Lundbeck sounds taps on another CNS drug, retreating from a mine field still occupied by a Merck team

5 years ago

RA, Novartis back GentiBio's seed round, plans to launch development of EngTreg therapies

5 years ago

Stem cell player ViaCyte expands collaboration with Gore to develop subcutaneous diabetes treatment

5 years ago

Less than 3 months after launch, the AveXis crew’s Taysha raises $95M Series B. Is an IPO next?

5 years ago

Myovant lands a fresh $200M loan as FDA marketing decision looms; Amarin goes it alone in Europe

5 years ago

Moderna CEO Stéphane Bancel outlines a prospective motherlode of Covid-19 vaccine revenue — will a backlash ...

5 years ago

Versant debuts Ridgeline's startup #4, armed with $30M and alternative TCR cell therapies for solid tumors

5 years ago

Covid-19 roundup: J&J and BARDA agree to $1 billion for 100 million doses; Plasma reduces mortality by 50% — ...

5 years ago

CF Foundation, Longwood team on new incubator for companies with cutting-edge CF treatments

5 years ago

FDA touts advanced manufacturing to address Covid-19 shortfalls

5 years ago

Deep tech, round 2: DCVC Bio bags $350M fund to chase the tip of the life science spear

5 years ago

Novavax heralds the latest positive snapshot of early-stage Covid-19 vaccine — so why did its stock briefly crater?

5 years ago

Karuna and Incyte scrap programs; More cash for the SPACs

5 years ago

Novartis says Kymriah reaches primary endpoint in new PhII, although numbers still to come

5 years ago

Covid-19 roundup: FDA commissioners call for more ‘concerted effort’ on convalescent plasma R&D; Regeneron boosts ...

5 years ago

AbbVie shrugs off $134M cash deals, quitting a neuro R&D pact with Voyager Therapeutics on vectorized antibody ...

5 years ago

Merck scoops up a PhII J&J discard in a bargain-basement deal. And this time they’re shooting at NASH

5 years ago

CureVac nabs a top Novartis scientist for CSO slot as mRNA vaccines seize the spotlight

5 years ago

OWS' Moncef Slaoui lambasts ‘insulting’ media coverage: 'How are you helping in this pandemic?'

5 years ago

IgGenix emerges from stealth with $10 million Series A hoping to re-engineer allergic cascade

5 years ago

AstraZeneca throws Redx a lifeline — in exchange for a preclinical fibrosis drug — with a promise of $17M in ...

5 years ago

First page Previous page 815 816 817818819 820 821 Next page Last page